Zelira Therapeutics Ltd is a renowned company that holds strong values and corporate philosophy. Committed to excellence, Zelira strives to deliver innovative and effective therapeutic solutions. Their dedication lies in improving the quality of life for patients through the development of clinically validated cannabis-based medicines. With a focus on research and development, Zelira aims to provide evidence-based treatments to address unmet medical needs. Their core principles revolve around integrity, collaboration, and patient-centricity. By maintaining ethical standards and fostering partnerships, Zelira Therapeutics Ltd empowers patients and healthcare practitioners alike, driving advancements in the field of medicinal cannabis.

Zelira Therapeutics Ltd is primarily present in Australia and the United States.

Zelira Therapeutics Ltd, a renowned biopharmaceutical company, has achieved several significant milestones. The company has successfully developed and commercialized innovative therapeutic solutions for various medical conditions. Zelira Therapeutics has witnessed notable milestones, including the establishment of strategic partnerships with leading research institutions and pharmaceutical companies. Additionally, they have obtained regulatory approvals for their groundbreaking pharmaceutical products, enhancing patient access to cutting-edge treatments. Zelira Therapeutics Ltd has demonstrated consistent dedication to pioneering research, driving innovation, and improving patient outcomes. With their unwavering commitment to scientific excellence, Zelira Therapeutics continues to redefine possibilities in the pharmaceutical industry.

Zelira Therapeutics Ltd is a renowned global therapeutic medicinal cannabis company. Founded in 2016, the company focuses on the development and commercialization of innovative pharmaceutical-grade cannabinoid-based therapies. With a mission to improve patients' quality of life, Zelira Therapeutics conducts extensive research to develop evidence-based medicinal cannabis treatments targeting a range of medical conditions. The company collaborates with leading researchers, clinicians, and health organizations to ensure the highest standards in product development. Zelira Therapeutics aims to bring effective and safe cannabis-based therapies to patients worldwide.

Zelira Therapeutics Ltd faces competition from various players in the market. Some of the main competitors of Zelira Therapeutics Ltd include prominent pharmaceutical companies such as GW Pharmaceuticals, Canopy Growth Corporation, and Aphria Inc. These companies also operate in the medical cannabis industry and offer a range of products and services similar to Zelira Therapeutics Ltd. Competition in the market drives innovation and fosters growth, allowing customers to choose from diverse options. Zelira Therapeutics Ltd continues to engage in strategic initiatives to differentiate itself and stay competitive in this dynamic market.

Zelira Therapeutics Ltd is primarily active in the pharmaceutical and healthcare industries.

The business model of Zelira Therapeutics Ltd revolves around developing and commercializing evidence-based pharmaceutical-grade cannabis products for the treatment of various medical conditions. As a leading global medicinal cannabis company, Zelira Therapeutics focuses on research, development, clinical trials, and partnerships to bring innovative therapeutic solutions to patients. With a patient-centered approach, Zelira Therapeutics aims to improve patients' quality of life by providing safe and effective alternative treatments. Through strategic partnerships and collaborations, the company ensures its products reach a wider market, expanding its global footprint in the rapidly evolving medicinal cannabis industry.

KGV kan i øjeblikket ikke beregnes for Zelira Therapeutics.

KUV kan i øjeblikket ikke beregnes for Zelira Therapeutics.

AlleAktien Kvalitetsscore for Zelira Therapeutics er 7/10.

Omsætningen kan i øjeblikket ikke beregnes for Zelira Therapeutics.

Overskuddet kan i øjeblikket ikke beregnes for Zelira Therapeutics.

Zelira Therapeutics Ltd is a global company in the pharmaceutical development and sales of medical marijuana products. The company was founded to enhance the development and sales of therapeutic and medical marijuana products. Zelira Therapeutics aims to serve its customers through innovative, effective, and safe products of exceptional quality and efficiency. The business model of Zelira Therapeutics is focused on being a leader in the medical marijuana industry. The company concentrates on innovative products tailored to the needs of patients and doctors. Zelira Therapeutics possesses extensive knowledge and collaboration with renowned companies to develop the latest and most advanced technologies and products. The company has various divisions that focus on the development of medical marijuana products. One of them is the research and development of products tailored to various therapeutic applications such as the treatment of chronic pain, sleep disorders, and inflammation. Zelira Therapeutics has also developed innovative products targeting patients with epilepsy and autism. Another focus of Zelira Therapeutics is the sale of medical marijuana. The company has partnerships with organizations specialized in the manufacturing and sale of medical marijuana. Zelira Therapeutics strives to serve its customers through effective and safe delivery of marijuana products. The company offers various products, including oral sprays, capsules, and topical creams. A popular product of Zelira Therapeutics is the oral spray, which provides a quick and effective method of administering marijuana. The company has also developed a range of topical creams that can be used for pain relief and inflammation. Capsules provide an excellent way to precisely control dosage. Zelira Therapeutics also has a department for international business activities. Here, the company focuses on collaborations with international partners to distribute its products worldwide. The International Business Development department has enabled the company to sell its products in various countries such as Australia, Germany, and Canada. Zelira Therapeutics also has plans to expand into new markets like the United Kingdom and Spain. Overall, Zelira Therapeutics offers differentiated products based on the needs of patients and therapy methods. The company strives to provide its customers with safe, effective, and high-quality marijuana products. With a strong focus on research and development and unique partnerships, Zelira Therapeutics is well-equipped to continue playing a leading role in the medical marijuana industry.

Zelira Therapeutics udbetaler et udbytte på 0 AUD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Zelira Therapeutics, eller selskabet udbetaler ikke udbytte.

ISIN'en for Zelira Therapeutics er AU000000ZLD1.

WKN for Zelira Therapeutics er A2AS5H.

Tickeren for Zelira Therapeutics er ZLD.AX.

I løbet af de sidste 12 måneder betalte Zelira Therapeutics en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Zelira Therapeutics sandsynligvis betale en dividende på 0 AUD.

Udbytteafkastet for Zelira Therapeutics er i øjeblikket .

Zelira Therapeutics betaler kvartalsvis udbytte. Dette uddeles i månederne .

Zelira Therapeutics betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 AUD. Dette svarer til et dividendeafkast på 0 %.

Zelira Therapeutics bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Zelira Therapeutics fra den 6.1.2025 på 0 AUD, skulle du have haft aktien i din portefølje før ex-datoen den 6.1.2025.

Udbetalingen af det sidste udbytte blev foretaget den 6.1.2025.

I løbet af 2024 udbetalte Zelira Therapeutics 0 AUD i form af dividender.

Udbytterne fra Zelira Therapeutics udbetales i AUD.